-
-
-
The present findings raise the possibility that new effective therapies may be developed for CMT2A, which target the underlying pathophysiology.
-
There is an increase in mortality with methylprednisolone in the 2 weeks after head injury. The cause of the rise in risk of death within 2 weeks is unclear.
-
This condition preferentially affects large myelinated fibers of the posterior roots, may respond favorably to treatment, and may be a restricted form of chronic inflammatory demyelinating polyradiculoneuropathy.
-
Further research will be required to understand the pathogenesis of these disorders.
-
This strategy yields potent inhibitors of A-beta aggregation and could lead to therapeutics for Alzheimers disease and other forms of neurodegeneration.
-
LRRK2 may be central to the pathogenesis of several major neurodegenerative disorders associated with Parkinsonism.
-
Natilizumab will become an important option for newly diagnosed MS patients starting treatment, or for patients currently on interferon beta-1a or glatiramer acetate with refractory breakthrough disease.
-
Given the importance of acute bacterial rhinosinusitis (ABRS), a commonly encountered outpatient infection, this article attempts to outline in evidence-based detail what the authors conclude to be optimal, risk-stratified, empiric treatment recommendations. In addition, this review identifies key clinical findings, resistance patterns, risk factors, coexisting conditions, and other clinical triggers supporting referral of patients with ABRS to an otolaryngologist for more invasive i.e., multimodal surgical and more intensive antimicrobial management strategies.